Huang YC, et al. - Researchers investigated the pro-inflammatory cytokine profiles in the severe allergic asthma patients who responded vs non-responded to omalizumab therapy. Among 23 patients with severe allergic asthma who were treated with omalizumab therapy, 14 improved their asthma control after 4 months of omalizumab treatment (Responders), while 9 failed to improve (Non-Responders). The analysis indicated that most of the responders were IL-33, IL-25 and TSLP aggravated type 2-high endotype. They recommend evaluating patients who partially responded to omalizumab treatment for rhinosinusitis or a mixed eosinophilic and neutrophilic airway inflammation.